Luspatercept-aamt
REBLOZYL® (luspatercept-aamt) is the first erythroid maturation agent (EMA) approved by the US Food and Drug Administration and European Union for the treatment of anemia anemia: (uh-NEE-mee-uh) A condition in which
treatment
Luca Malcovati, MD
Institution
IRCCS S. Matteo Hospital Foundation & University of Pavia
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Aplastic Anemia
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
About
Dr. Malcovati is an Associate Professor of Hematology at the University of Pavia Medical School and with special interest and expertise in myeloid neoplasms, in particular, myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms. Dr. Malcovati's research group has made a significant contribution to understanding the molecular basis of myeloid neoplasms and to the integration of somatic mutations in the clinical management of patients.
Joseph Oved, MD
Institution
Memorial Sloan-Kettering Cancer Center
Physician Status
accepting new patients
Primary Disease Area of Focus
Aplastic Anemia
Pediatric
About
Dr. Oved completed scientific and clinical training that included tenures as a Fulbright Fellow with the Weizmann Institute in Israel, the NYU School of Medicine with two years as a Howard Hughes Medical Fellow, followed by a residency in Pediatrics at NYP Weill Cornell Medical College. During his residency, he developed an interest in more translational questions working with Dr. James Bussel to test a novel combination of dexamethasone and rituximab for pediatric patients with chronic idiopathic thrombocytopenic purpura (ITP).
Ramiro Garzon, MD
Institution
University of Utah School of Medicine
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)